Clinical trial
A Study to Evaluate the Efficacy and Safety of Subcutaneous MK-3222, Followed by…
NCT01722331 · Sun Pharmaceutical Industries Limited, Industry · Completed
Key facts
| NCT number | NCT01722331 |
|---|---|
| Title | A Study to Evaluate the Efficacy and Safety of Subcutaneous MK-3222, Followed by an Optional Long-Term Safety Extension Study, in Participants With Moderate-to-Severe Chronic Plaque Psoriasis (MK-3222-010) |
| Official title | A 64-Week, Phase 3, Randomized, Placebo-Controlled, Parallel Design Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous Tildrakizumab (SCH 900222/MK-3222), Followed by an Optional Long-Term Safety Extension Study, in Subjects With Moderate-to-Severe Chronic Plaque Psoriasis… |
| Acronym | reSURFACE 1 |
| Lead sponsor | Sun Pharmaceutical Industries Limited, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Plaque Psoriasis |
| Intervention type | Drug |
| Interventions | Tildrakizumab 200 mg, Tildrakizumab 100 mg, Matching Placebo |
| Enrollment | 772 |
| Start date | Dec 6, 2012 |
| Primary completion | Oct 28, 2015 |
| Completion | Nov 10, 2021 |
| First posted | Nov 6, 2012 |
| Last update posted | Mar 23, 2022 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: